| Literature DB >> 31888646 |
María Merino1, Renata Villoro2, Álvaro Hidalgo-Vega2,3, Concepción Carmona4.
Abstract
BACKGROUND: COPD is a high prevalence chronic disease that involves large reductions of health-related quality of life (HRQL) of patients. This study aims to describe the HRQL of patients with COPD in Extremadura (Spain).Entities:
Keywords: EQ-5D-5L; Health-related quality of life; Obstructive pulmonary disease; Primary care; SGRQ-C; Spain
Mesh:
Year: 2019 PMID: 31888646 PMCID: PMC6937847 DOI: 10.1186/s12955-019-1244-4
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Sociodemographic and clinical characteristics of the sample
| Variable | Subcategory | Total |
|---|---|---|
| Gender (%) | Male | 76.2% |
| Female | 23.8% | |
| Age in years (mean ± SD) | 71.8 ± 10.3 | |
| Age group (%) | Under 65 | 20.7% |
| 65 years or older | 79.3% | |
| Smoking history (%) | Current smoker | 16.7% |
| Ex-smoker | 69.6% | |
| Never smoked | 13.7% | |
| Daily cigarettes (mean ± SD) | Smokers | 14.1 ± 10.3 |
| Ex-smokers | 27.3 ± 16.4 | |
| Education level (%) | Does not know how to read or write | 6.0% |
| No education | 33.9% | |
| Primary education | 35.9% | |
| Secondary education | 18.5% | |
| University education | 5.7% | |
| Employment status (%) | Early retirement/retired | 78.9% |
| Actively working | 7.9% | |
| Domestic work | 7.1% | |
| Unemployed | 3.4% | |
| Permanent leave | 1.6% | |
| Temporary leave | 1.1% | |
| FEV1/FVC (mean ± SD)a | 60.3 ± 18.7 | |
| FEV1% (mean ± SD)b | 66.7 ± 22.3 | |
| Level of severity (%) | GOLD I | 10.9% |
| GOLD II | 20.5% | |
| GOLD III | 9.1% | |
| GOLD IV | 1.3% | |
| Unknown/not available | 58.3% | |
| Presence of exacerbations in the last 12 months (%)c | 36.7% | |
| Number of exacerbations in the last 12 months (mean ± SD)c | 0.6 ± 1.2 | |
| Number of comorbidities (mean ± SD) | 7.0 ± 4.0 | |
| Main comorbidities (%) | Cardiovascular comorbidityd | 57.5% |
| Dyslipidaemia/Lipid metabolism disorder | 41.5% | |
| Uncomplicated hypertension | 38.3% | |
| Diabetes Mellitus (type 1 + type 2) | 27.2% | |
| Arthritis/Arthrosis | 20.0% | |
| Cancer/malignancy | 14.8% | |
| Hypertension with target organ involvement | 13.0% | |
| Anaemia | 6.7% | |
| Depression | 6.2% | |
| Asthma | 6.0% | |
| Osteoporosis | 3.9% | |
| BMI (mean ± SD)e | 30.0 ± 5.0 | |
| Classification of BMI according to the WHO (%) | Insufficient weight | 0.8% |
| Normal weight | 3.4% | |
| Overweight | 16.1% | |
| Obesity | 18.4% | |
| Unknown/not available | 61.4% |
SD standard deviation, FEV forced expiratory volume in the first second, absolute value, FVC forced vital capacity, FEV% forced expiratory volume in the first second, percentage value, COPD chronic obstructive pulmonary disease, BMI Body Mass Index, MRC Medical Research Council, WHO World Health Organization. Number of valid cases: 386, unless specifically indicated. aNumber of valid cases: 123; bNumber of valid cases: 140; cNumber of valid cases: 215; dIncludes unspecified cardiac arrhythmia, atherosclerosis or peripheral arterial disease, valvular heart disease, atrial fibrillation/atrial flutter, acute myocardial infarction, heart failure, cardiac ischaemia with angina, cardiac ischaemia without angina, other cardiac diseases, other cardiovascular diseases, other cardiovascular signs/symptoms, and paroxysmal tachycardia; eNumber of valid cases: 149
Fig. 1EQ-5D-5L dimensions. Total (a), based on level of severity (b), based of gender (c), and based on age group (d)
EQ-5D-5L: Utility and VAS. Total and subgroups (level of severity, gender and age group)
| Subgroups | Number of valid cases | Utility | VAS | ||
|---|---|---|---|---|---|
| mean ± SD | mean ± SD | ||||
| Level of severity | |||||
| GOLD I | 41 | 0.74 ± 0.35 | 0.003 | 59.8 ± 24.4 | 0.040 |
| GOLD II | 79 | 0.77 ± 0.26 | 62.4 ± 20.7 | ||
| GOLD III | 35 | 0.58 ± 0.31 | 50.0 ± 21.2 | ||
| GOLD IV | 5 | 0.48 ± 0.45 | 65.7 ± 30.1 | ||
| Gender | |||||
| Male | 308 | 0.76 ± 0.28 | < 0.001 | 60.5 ± 22.0 | 0.001 |
| Female | 78 | 0.58 ± 0.38 | 51.3 ± 20.0 | ||
| Age group | |||||
| Under 65 | 80 | 0.81 ± 0.22 | 0.023 | 59.3 ± 20.7 | 0.837 |
| 65 years or older | 306 | 0.70 ± 0.32 | 58.5 ± 22.3 | ||
| Total | 386 | 0.72 ± 0.31 | 58.6 ± 21.9 | ||
EQ-5D-5L EuroQol - 5 dimensions - 5 levels, VAS visual analogue scale, SD standard deviation, COPD chronic obstructive pulmonary disease
SGRQ-C Score. Total and based on subgroups (level of severity, gender and age group)
| Subgroups | Number of valid cases | Symptoms | Activity | Impacts | Total score | ||||
|---|---|---|---|---|---|---|---|---|---|
| mean ± SD | mean ± SD | mean ± SD | mean ± SD | ||||||
| Level of severity | |||||||||
| GOLD I | 41 | 38.6 ± 22.6 | < 0.001 | 45.7 ± 28.8 | < 0.001 | 27.6 ± 26.8 | 0.001 | 35.1 ± 25.1 | < 0.001 |
| GOLD II | 79 | 40.3 ± 22.1 | 53.2 ± 25.9 | 33.4 ± 26.8 | 40.7 ± 23.6 | ||||
| GOLD III | 35 | 62.3 ± 23.0 | 73.5 ± 23.3 | 54.8 ± 28.9 | 61.9 ± 24.8 | ||||
| GOLD IV | 5 | 55.1 ± 26.1 | 70.1 ± 25.5 | 46.3 ± 33.7 | 55.2 ± 28.2 | ||||
| Gender | |||||||||
| Male | 308 | 41.6 ± 23.1 | 0.256 | 50.6 ± 28.5 | 0.004 | 31.1 ± 27.2 | 0.002 | 39.0 ± 24.9 | 0.003 |
| Female | 78 | 44.4 ± 23.3 | 61.3 ± 28.0 | 42.0 ± 26.9 | 48.4 ± 24.3 | ||||
| Age group | |||||||||
| Under 65 | 80 | 39.8 ± 22.2 | 0.376 | 44.7 ± 28.7 | 0.006 | 28.8 ± 24.7 | 0.167 | 35.6 ± 23.4 | 0.052 |
| 65 years or older | 306 | 42.8 ± 23.4 | 54.8 ± 28.4 | 34.5 ± 28.1 | 42.2 ± 25.3 | ||||
| Total | 386 | 42.2 ± 23.2 | 52.7 ± 28.7 | 33.3 ± 27.5 | 40.9 ± 25.0 | ||||
SGRQ-C St. George Respiratory Questionnaire – COPD, COPD chronic obstructive pulmonary disease, SD standard deviation. Columns 3 to 6 show the mean and SD that correspond to the number of valid cases shown on column 2
Results of stepwise multiple regression models for utility (EQ-5D-5L) and total score (SGRQ-C)
| Dependent variable | Explanatory variablesa | B coefficientb | 95% CI | Coefficient of determination | |
|---|---|---|---|---|---|
| Total score (SGRQ-C) | Intercept | 35.604 | < 0.001 | (29.278; −41.930) | 0.431 |
| Level of severity | 21.267 | < 0.001 | (12.119; 30.416) | ||
| Number of exacerbations in the past 12 months | 8.445 | < 0.001 | (5.140; 11.749) | ||
| Education level | −18.147 | < 0.001 | (−27.469; −8.824) | ||
| Gender | 19.693 | < 0.001 | (8.864; 30.523) | ||
| Utility (EQ-5D-5L) | Intercept | 0.763 | < 0.001 | (0.684; −0.842) | 0.296 |
| Number of exacerbations in the last 12 months | −0.086 | < 0.001 | (− 0.127; − 0.044) | ||
| Level of severity | −0.176 | 0.003 | (−0.291; − 0.061) | ||
| Education level | 0.188 | 0.002 | (0.071; 0.305) | ||
| Gender | −0.157 | 0.024 | (−0.293; − 0.021) |
CI confidence interval, EQ-5D-5L EuroQol - 5 dimensions - 5 levels, SGRQ-C St. George Respiratory Questionnaire – COPD
aExplanatory variables included in the models: gender (0: male (reference category)/1: female), age in years, education level (0: no education and primary education (reference category)/1: secondary and university education), level of severity (0: GOLD I-II (reference category)/1: GOLD III-IV), number of exacerbations in the last 12 months and number of comorbidities
bUnstandardized B coefficient